Trial Profile
Randomized, Placebo Controlled Double Blind, Multi-center Phase II Proof-of-concept Study to Assess the Efficacy of AIN457 in Patients With Moderate to Severe Ankylosing Spondylitis
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Secukinumab (Primary)
- Indications Ankylosing spondylitis
- Focus Proof of concept; Therapeutic Use
- Sponsors Novartis
- 06 Aug 2015 Results published in the Annals of the Rheumatic Diseases.
- 13 Sep 2013 Results published in the Lancet.
- 14 Nov 2012 Biomarker analysis presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.